Leqembi (lecanemab) prior authorization denied appeal
Anti-amyloid mAb for early symptomatic Alzheimer's
Typical PA criteria
- Mild cognitive impairment or mild AD dementia with confirmed amyloid pathology (PET or CSF)
- MMSE 22–30 or equivalent
- MRI screening for microhemorrhages/ARIA baseline
- ApoE4 genotype recommended
- Neurology or memory-clinic prescriber
Why your PA was denied
- Amyloid confirmation not documented
- MMSE outside range
- Baseline MRI missing
- Medicare coverage restrictions (CMS registry requirement)
Evidence that overturns the denial
- ✓Amyloid PET or CSF Aβ42/40 result
- ✓MMSE or MoCA baseline
- ✓Baseline MRI
- ✓Neurology letter with staging
Medicare covers Leqembi under a CMS registry (CED) requirement; participation in the registry is a coverage prerequisite for Traditional Medicare. Commercial plans mirror clinical trial inclusion criteria.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Leqembi (lecanemab) prior authorization denied?+
The most common reasons are: Amyloid confirmation not documented; MMSE outside range; Baseline MRI missing. Your denial letter names the specific criteria you did not meet.
How do I appeal a Leqembi (lecanemab) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Leqembi (lecanemab) denial?+
Amyloid PET or CSF Aβ42/40 result; MMSE or MoCA baseline; Baseline MRI.
What if the plan excludes Leqembi (lecanemab) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)